FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **SONA Nanotech Inc.** (“Sona” or “Issuer” or “Company”).

Trading Symbol: **SONA**

Number of Outstanding Listed Securities: **99,145,361**

Date: **May 6, 2024 *(for the month of April 2024)***

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nano technologies may be adapted for use in applications as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards.*

*Sona has applied for patent protection in five major jurisdictions on its technology for the manufacture of GNRs that offers several functional performance advantages over other particles currently in the market, such as:*

* *Sona GNRs are manufactured without the use of CTAB, a known toxin, that is typically used in GNR production. The absence of CTAB in Sona’s proprietary manufacturing process may confer on Sona GNR’s an advantage over other GNR in terms of their biocompatibility which may be important for various developing in vivo medical applications of GNRs.*
* *Sona GNRs are designed to maximize the ability to detect bio markers in low concentration levels, essentially meaning Sona tests may be able to detect a condition earlier than many other particles.*
* *Sona GNRs can move through lateral flow test membranes at a faster pace than other particle types, meaning the Sona test may be able to produce results faster than many other lateral flow tests.*
* *Sona GNRs can be manufactured in various sizes which allow multiple colour test lines to be generated, providing a simple differentiation between test and control results, whereas competitive spherical gold nanoparticles can only present as a red line.*

*For its GNR IP advancement strategic priority, Sona is undertaking an R&D program to enhance its understanding of its proprietary biocompatible, GNR manufacturing technology with the goal of identifying the most promising advanced biomedical applications for it to pursue. To accomplish this, Sona plans to partner with leaders in the bioengineering and nanotechnology fields to conduct a series of experiments and studies to better understand the effects of using its GNRs in medical therapies to gain insights into which would be best to pursue.*

*This is an important priority given that Sona’s biocompatible GNRs address the primary concern in the development and adoption of medical therapies involving the use of GNRs within the body, or ‘in vivo’. That concern is for the toxicity associated with the preparation of other GNRs, and potential negative health impacts. The manufacture of Sona’s GNRs, meanwhile, uniquely does not involve the use of CTAB, a substance well-known to be toxic. Continuing to strengthen Sona’s IP is a key element in its ambition for the leadership position for its GNRs for in vivo medical applications.*

1. Provide a general overview and discussion of the activities of management.

*Management continues to guide the development of rapid diagnostic tests and discussions with potential partners for the development and commercialization of rapid tests, as well as for R&D associated with the Company’s GNR manufacturing technology, scientific experience, and laboratory asset.*

*Nanotechnology Characterization Laboratory Assessment of Gold Nanorods*

*In February 2023 the Company received the results of an independent assessment of its proprietary gold nanorod nanoparticles from the US National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”). The assessment included analyses of three batches of Sona’s materials for microbial contamination, endotoxin levels, Beta-glucan, physiochemical characterization, and polyethylene glycol (“PEG”) concentrations.*

*The analyses determined that endotoxins and microbial contamination were “undetectable” based on both turbidity and chromogenic limulus amebocyte lysate (“LAL”) assays and the NCL’s endotoxin limit. While beta-glucan levels varied across the samples, they were all within limits of what is normally present in the blood from dietary sources. Also, no free PEG was detected in any of the three batches of materials provided.*

*The results of the NCL’s characterization of Sona’s biocompatible gold nanorod nanoparticles indicate that they are expected to be compatible for use in vivo with Siva’s Targeted Hyperthermia Therapy, as ruling out the material presence of endotoxins was key to enabling our further work together towards preparations for clinical trials.*

*In April 2023, the Company received the second set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the NCL. The assessment included analyses of two additional batches of Sona’s gold nanorods for consistency of physiochemical characterization and microbial contamination and endotoxin levels. The assessment also found “no significant differences between the two lots by DLS (dynamic light scattering) hydrodynamic size, zeta potential, or gold concentration”.*

*In early June 2023, the Company received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the NCL. In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant residue present following the chemical reaction necessary for the manufacture of Sona’s proprietary gold nanorods. The assessment shows that the continued improvements in Sona’s manufacturing process for gold nanorods have resulted in a significant reduction in free surfactant levels in nanorod dispersions, with the average dropping from 230.7 ug/mL in prior assessed batches to 34.6 ug/mL in the batches following the process changes.*

*In March 2024, the Company received its final report from the NCL of its polymer-coated gold nanorods, which included a third assessment of material from Sona, bringing the number of batches of Sona material validated by the NCL to a total of seven. The most recent assessment found improved physical uniformity (with all three batches measuring within 2.1 nanometers in length of each other) and greater purity when compared to past batches. These improvements have been achieved via certain manufacturing process improvements developed with the support of the NCL, and which, in addition to improving purity, may result in reduced costs of scaled manufacturing. This final report also confirmed that the data between all lots of the material that have been assessed are in general agreement.*

*The studies conducted by NCL included endotoxin testing, hydrodynamic size by DLS, size and shape distribution by TEM, zeta potential, total gold concentration by inductively coupled plasma mass spectrometry (ICP-MS), total and free PEG and total surfactant concentration using RP-HPLC-CAD, and total gold concentration using ICP-MS.*

*The NCL was established by the National Cancer Institute (“NCI”) to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration (“FDA”), and the National Institute of Standards and Technology (“NIST”). It is anticipated that the NCL report could be used in a future potential regulatory application for an investigational device exemption (“IDE”) to support the biocompatibility of Sona’s gold nanorods.*

*Sona Powered Rapid Test Development Program*

*Sona’s GNR technology can be used in a variety of lateral flow assay applications. In a lateral flow test, particles such as Sona’s GNRs are used to bind to biological materials and carried along a test strip, producing a positive or negative result.*

*For its test and reagent development business, Sona will continue to develop proprietary rapid diagnostic tests and associated biologic reagents for the medical and other industries. The Company has also begun to offer the same services to third parties. Providing this service is an important addition as it is highly complementary to the laboratory-based work for Sona’s proprietary development business and is expected to be undertaken on a ‘fee for service’ basis, which has the potential to generate revenue in the near-term. The Company aims to use its network and reputation for quickly developing rapid diagnostic test prototypes and reagents to secure profitable business opportunities.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*Sona’s Bovine TB Test*

*In May 2021, the Company announced that it is receiving advisory services and up to $457,830 in funding support from the National Research Council of Canada (“NRC”) Industrial Research Assistance Program (“IRAP”) to support a research project in association with a consortium of UK companies to develop a bovine tuberculosis (“bTB”) rapid test. NRC’s IRAP contribution was approved under a program to promote collaborative projects with UK partners through the Canada-UK industrial research and development call for proposals delivered by the National Research Council of Canada and UK Research and Innovation.*

*As part of the multi-year project, Sona will work closely with other consortium members to leverage bTB biomarker research from Aberystwyth University to develop a rapid, lateral flow assay to identify bTB that differentiates between vaccinated and unvaccinated cows. The consortium also intends to develop a data collection infrastructure system to enable authorities to detect, manage and control movement of infected animals. UK Research and Development are supporting other members of the consortium with funding to assist in the goal of eradicating bTB in the UK.*

*Accurate and timely detection, herd management and movement control are critical to eradicating this communicable disease which is still prevalent in many areas of the World. Currently, a diagnosis is made through post-mortem examination and tissue culture, which can take up to 12 weeks. Once bTB is confirmed, all infected and exposed animals in a herd are typically destroyed. bTB control measures cost over £500 million in the last 10 years and without intervention, the UK government expects costs to top £1 billion over the next decade if no new action is taken. bTB is also an issue in the European Union where, in 2018, 7.5 million statutory bTB lab-based, screening tests were carried out across seven countries, including France, Belgium, Italy and the UK.*

*In September 2021 Sona announced that its bovine tuberculosis (“bTB”) test has been advanced with the identification of multiple biomarkers that can not only be used to detect the presence of bTB bacteria, but, as set, are able to differentiate whether the bacteria is present due to an ongoing infection or as a result of vaccination. The biomarkers that have been identified to be used in the assay have been synthesized into different antigens which will be used to develop the polyclonal antibodies for use in a multiplex lateral flow assay. The primary biomarker of interest has now been converted into a polyclonal antibody and is being incorporated into a test strip format that will test for the presence of infection in blood. Polyclonal antibodies of a second and third biomarker are also being generated for purification and incorporation into the test. A prototype, testing for the first of three biomarkers, has been completed and assessed in lab using whole bovine blood, serum and plasma spiked with antigen providing viable results. Work will continue to optimize the test performance prior to assessing the device with clinical samples of known bTB status in lab and then in the field. Following successful clinical testing, integration of biomarker 2 and 3 antibodies would be assessed if and when required materials are available.*

*In November 2022, the Company entered a memorandum of understanding (“MOU”) with Biotangents Limited (“Biotangents”) to evaluate, and if determined effective, to commercialize its bTB rapid test. Under the terms of the MOU, the parties plan to explore the characteristics of Sona’s bTB test and its suitability for commercialization. Biotangents will provide Sona with consultation on the design and execution of appropriate clinical evaluation studies to determine performance of the test prototype. Biotangents has been granted a ‘first right of refusal’ to license Sona’s bTB test technology for the purposes of commercialization on mutually agreeable terms.*

*Sona uses its own proprietary bTB antibodies in its bTB prototype test which has recently been assessed against clinical samples of known status. Samples from cattle deemed positive for bTB, via the tuberculin skin test (“SICCT”), and samples from a bTB-free herd were both assessed in a recent study. Results show that the test generated a Positive Predictive Value (“PPV”) of 80% (24/30 samples) and a Negative Predictive Value (“NPV”) of 96% (29/30 samples). While the Company is pleased with these confirmatory initial results, it cautions that further clinical assessments will be required to validate the results to date. The initial results of the Sona rapid screening assay are very promising and if proven to be successful in the field, could be an excellent addition of the toolkit that vets and farmers can use in the fight against bovine TB. Sona intends to pursue this work with relevant institutions in order to provide the evidence necessary to support a successful commercialization of the test.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*Not applicable.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*Research Initiative with the Giacomantonio Immuno-Oncology Research Group*

*Sona has engaged the Giacomantonio Immuno-Oncology Research Group (the “Research Group”) to undertake an innovative research initiative to evaluate the efficacy of Sona's THT technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses. (the “Study”) The study posits that the combined utilization of Sona's gold nanorods via its THT, alongside precise immune modulation, will result in elevated immune activation and anti-tumor responses within the mouse models of colorectal cancer, breast cancer, and melanoma.*

*This innovative study will go significantly beyond our current plans for THT applications to explore the potentially synergistic effect of its use with certain immunotherapy treatments for cancer. In it, Sona aims to harness the tremendous potential of immunotherapy, leveraging its biocompatible gold nanorods as a pivotal, catalytic element. This effort marks the beginning of Sona delivering on the ‘mountain of data’ we committed to developing in support of our planned regulatory submissions for human clinical trial approvals.*

*The Research Group will explore two distinct yet interrelated biological processes with the potential to unlock the elusive Holy Grail of intra-tumoral cancer immunotherapies, known as the Abscopal Effect. The first avenue capitalizes on the kinetic excitation of gold nanorods, capable of inducing localized tumor destruction. This process exposes potent tumor neo-antigens, which can then be strategically mobilized to immune-responsive sites. This strategy holds the potential of profoundly reshaping and amplifying the efficacy of the immune response against cancer. Concurrently, the second dimension of the research delves into the profound impact of intralesional immunomodulation in the context of both local and systemic THT.*

*The planned studies will bring the extensive knowledge and experience of the Research Group to bear in an elegant and sophisticated study that will increase our understanding of both the mechanisms and capabilities of THT. The findings of this study will help inform and improve our planned first-in-human studies as we approach that important milestone.*

*To facilitate the study, the Company and the Research Group have entered into a Research Agreement under which the experiments will be conducted. The experiments will explore immune reprogramming by tumor antigen transfer as well as tumor response and immune modulation in subcutaneous tumor models following treatment with various immunotherapeutic interventions. The Company will cover up to a maximum of $80,000, which is approximately 40% of the study’s anticipated cost, which will include in-kind contributions from the Company and its laboratory.*

*The current study assesses the THT efficacy of using Sona’s gold nanorods for their combined effect both in generating Targeted Hyperthermia in tumors exposed to near infrared light and as an immune modulator locally and in distant, untreated tumors. This portion of the study will continue to look for elevated immune activation and anti-tumor responses within the mouse models of breast cancer, melanoma and colorectal cancer, using THT alone and in combination with selected immunological agents commonly used in current cancer treatment protocols.*

*The initial assessment documented that in cohorts of seven animals, 7/7 of treated triple negative breast cancer mouse tumors bearing gold nanorods responded with an average reduction in tumor volume of 80% following a single treatment with near infrared light in comparison with untreated ‘control’ tumors.*

*In early April 2024, the Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona’s targeted hyperthermia therapy (“THT”) and interleukin-2 (“IL-2”), a standard immunotherapy, is statistically significantly superior to results observed from treatment with either agent individually or the control group. This second phase of the Study has documented that, in a cohort of six animals, 6/6 of treated triple negative breast cancer, the most aggressive and therapy resistant form, mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, resulting in a flattening of the tumor growth curves, as shown in the below graph. The generation of hyperthermia involved exposing tumors previously injected intratumorally with Sona’s gold nanorods and IL-2 to a single dose of near infrared light.*

*In late April 2024, the Company received further results which confirm that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These data relate to the follow-up biomarker analysis performed on the previously reported cohort of animals that showed a statistically significant synergistic effect in the shrinking of both treated and untreated tumors in animals bearing multiple tumors after treatment with the combination of Sona’s targeted hyperthermia therapy (“THT”) and interleukin-2 (“IL-2”), an immunotherapy agent widely used to treat human cancer patients.*

*The fluorescence-activated cell sorting (“FACS”) analysis of the tumor infiltrating cells looking at two panels of 12 biomarkers demonstrated a statistically significant cytotoxic T-cell infiltrate in both treated tumors and the untreated (contralateral) tumors, confirming a systemic immune response, consistent with an abscopal effect, in the treated mice treated with the combined THT and IL-2 therapy that is not seen in the other groups. Also notable is the fact that cytotoxic T-cells in treated tumors express significantly more immune checkpoint indicating potential for additional benefits.*

*The Study consisted of 26 mice bearing multiple triple negative breast cancer tumors, including a control group of six, seven given IL-2 only, and seven given THT only, as well as the cohort of six mice that were administered the combination of the generation of hyperthermia followed by intratumoral injections with IL-2. The Study’s next step is to assess the therapy’s ability to generate similar results in melanoma and colorectal cancer mouse models and determine the extent to which it eliminates untreated distant tumors for these cancers.*

*The results discussed in this release are preliminary and have not been subject to peer review. Upon completion, the Company expects that the full Study will be submitted for peer review and scientific journal publication.*

*Following the additional melanoma and colorectal experiments in the Study, regulatory permission to conduct human trials will require certain satisfactory pre-clinical safety and biocompatibility studies, amongst other potential work. The Company has received guidance on its pre-clinical study plan from both a pre-submission meeting with the Food and Drug Administration and its EXCITE International panel of senior physicians and payor organization representatives in the United States.*

*EXCITE International Partnership*

*Sona has partnered with EXCITE International (“EXCITE”), a global network of senior specialist physicians, payors, health systems, and end-users, to help guide the development of Sona’s THT. Through this partnership with EXCITE, Sona will gain access to EXCITE’s global network to help it align pre-clinical and clinical trial design and regulatory strategy with the interests of specialist practitioner and potential payor groups.*

*The work to be completed by EXCITE, which is a not-for-profit entity made up of a global network of senior medical practitioners and payors, will include an Early Technology Review and multiple panel discussions to be facilitated among content area experts to gain feedback on Sona’s proposed therapy and commercialization strategy. The EXCITE panel is expected to be made up of senior medical practitioners from top-tier hospitals and universities in the US and Canada.*

*EXCITE will put Sona’s THT in front of leading oncologists and medical coverage insurance providers to give the Company early feedback to help ensure that the therapy being developed is done in a way such that what is delivered is what patients, practitioners and payors will value, prescribe and pay for, respectively. EXCITE is known for attracting leading physicians and representatives from payor organizations, and Sona looks forward to working with these individuals to gain their guidance over the next few months with the aim to de-risk our approach and speed our time to market.*

*EXCITE offers early direct engagement with experts and payers through early technology review, protocol development, and clinical trial execution. This allows companies to anticipate and meet the downstream expectations of these important stakeholders. EXCITE is selective in only taking on potentially impactful technologies that offer improved patient outcomes and/or health system efficiencies.*

*The Company also recently met with a group of leading surgeons and payer representatives in the U.S as part of its second EXCITE International panel discussion. That roundtable evaluation and discussion, together with its recent pre-submission meeting with the U.S. Food and Drug Administration ("FDA"), provided important feedback and guidance to the Company on the development and validation path for its THT cancer therapy.*

*This roundtable session with its panel of surgeons from leading U.S. academic medical centres and medical payment organizations provided the Company with invaluable counsel on considerations for both the 'indications for use' for Sona's THT and the research data that may be required to secure payment codes from payers. This guidance, together with recent feedback received from the FDA, gives us confidence in the appropriateness of our research study pathway and the likelihood of acceptance by physicians and healthcare institutions of our cancer treatment. The Company continues to develop the data on the safety and efficacy of its therapy to support an eventual regulatory submission with its current study at Dalhousie University Medical School.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*Not applicable.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*In May 2023, Sona entered an agreement for the sale of its non-core interest in the Crescent Lake lithium property located in Ontario, Canada (“Property”) to an arm's length party, Midex Resources Ltd. (“Midex”), has been finalized (“Midex Agreement” or “Transaction”).*

*The Property was acquired by Antler Gold Inc. (“Antler”) from Sona in May 2019 pursuant to a property acquisition agreement (“2019 Agreement”). Under the 2019 Agreement, Sona is entitled to receive 50% of the consideration received by Antler for the Property, net of Antler’s aggregate expenses related to the marketing, selling, upkeep and maintenance of the Property (“Antler’s Expenses”) incurred between the disposition of the Property to Antler and the date of the sale of the Property.*

*Under the Midex Agreement, Antler has agreed to sell the Property to Midex in consideration of C$125,000 in cash (the “Cash Consideration”) and the issuance of common shares of Midex (“Midex Shares”) representing 12% of the issued and outstanding capital of Midex, subject to certain adjustments (the “Share Consideration”).*

*The Company received $42,639 for its share of the cash consideration which was net of Antler’s approved Expenses.*

*Midex will register 50% of the Share Consideration in the name of Sona. Each of Antler and Sona entered into an investor rights agreement with Midex in relation to the Midex Shares. Midex has not completed its go-public transaction and the Company has not yet received its final Share Consideration. An additional gain on sale of this Property will be recorded upon receipt of the Midex shares. The Midex Shares will be subject to certain resale restrictions and escrow conditions.*

1. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

*Sona filed an International (PCT) Patent Application on November 2, 2018, with a priority date of November 4, 2017, to protect their core gold nanorod technology. Sona has applied for and been granted patent protection in one territory with North America and Europe approvals pending on its technology for the manufacture of GNRs that offers several functional performance advantages over other particles currently in the market Upon issuance, the patents are expected to expire no earlier than November 2038 and will provide patent protection for Sona's gold nanorod technology.*

*In March 2024, the Company submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "Endoscope with EMR optical fiber and thermal sensor for photothermal therapy".*

*A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high intensity infrared laser light. The device has been designed for use with Sona's patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the Company's ongoing pre-clinical efficacy study of its THT cancer treatment at Dalhousie University.*

*In April 2024, the Company was awarded funding of $40,000 to support the development of an intellectual property strategy for Sona’s proprietary gold nanorods for* *novel targeted drug delivery concepts with a view to securing new patents. This funding will also support the final drafting and filing of a provisional patent for a novel targeted drug delivery concept being developed by the Company.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*As a result of the acquisition of Siva Therapeutics Inc. in March 2023, Leonard Pagliaro, Ph.D., CEO of Siva will now serve as Chief Scientific Officer of Sona and president of Sona’s wholly owned US subsidiary, Siva Therapeutics, Inc.* *Sona’s Darren Rowles will assume the new role of Head of Diagnostics for Sona and continue to drive the development of Sona’s rapid concussion and bovine tuberculosis tests, both of which also rely upon Sona’s biocompatible gold nanorod platform technology.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*Not applicable.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*On December 17, 2020, a putative shareholder class action lawsuit was filed in the United States District Court for the Central District of California. The complaint asserted claims under Sections 10(b) and 20 of the Securities Exchange Act of 1934 on behalf of a putative class of investors who purchased or otherwise acquired stock of the Company in US transactions between March 18, 2020 and February 28, 2021. The suit alleges that the Company made material misstatements regarding its rapid detection COVID-19 antigen test. On October 28, 2021, the United States District Court for the Central District of California issued an order granting the Company’s motion to dismiss and granted leave to the plaintiff to file an amended complaint within 14 days. During November, the plaintiffs filed an amended complaint which the Company has refuted with a motion to dismiss the amended action. On March 18, 2022, US Court granted the Company’s motion to dismiss without leave to amend and has entered a final judgement of the dismissal with prejudice. The 30 day appeal period expired on April 18, 2022.*

*On December 18, 2020, a Notice of Action and Statement of Claim was filed in the Supreme Court of Nova Scotia. The Statement of Claim purports to assert claims on behalf of a class of persons or entities who purchased stock of the Company based on similar allegations of material misrepresentations and omissions as alleged in the US action. The case is in its early stages.*

*The Company believes these claims are without merit and intends to contest the claims and mount a vigorous defence.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*Not applicable.*

1. Provide details of any securities issued and options or warrants granted.

*In February 2023, the Company completed its non-brokered private placement with the issuance of 11,000,000 shares at $0.10 per share (the “Financing”). These shares are subject to resale restrictions for a period of 4 months and a day form their date of issue.*

*In March 2023, the Company granted 1,225,000 incentive stock options under the Company's Stock Option Plan, of which 1,175,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.17 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant.*

*In July 2023, the Company granted 900,000 incentive stock options under the Company's Stock Option Plan, of which 825,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.25 per share. 600,000 options will vest at the rate of 25% every six months and 300,000 options issued to Officers are performance-based options tied to specific goals of the Targeted Hyperthermia Therapy program. The options will expire five years from the date of grant.*

*On November 27, 2023, and December 4, 2023, the Company closed a private placement with the issuance of 4,050,000 shares at $0.20 per share and a total of 2,025,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share. 1,875,000 of the warrants expire on November 24, 2025, and 150,000 expire on December 4, 2025. (the “Financing”). Insiders subscribed for 175,000 common shares and 87,500 common share purchase warrants. All securities issued pursuant to the Financing will be subject to a hold period until March 25, 2024.*

*Numus Capital Corp. (the “Agent”), a registered Exempt Market Dealer, acted as exclusive agent for the Financing**. In connection with the private placement, Sona paid the Agent cash commissions of $58,125 and 290,625 non-transferable share purchase warrants (the “Broker Warrants”). Each Broker Warrant entitles the holder to acquire one Share at an exercise price of $0.30. 268,125 of the broker warrants expire on November 24, 2025, and 22,500 expire on December 4, 2025. The Agent is a related party to Sona, a director of Sona being indirectly a principal shareholder of the Agent, as well such director of Sona also being a director and officer of the Agent.*

*On March 1, 2024, the Company granted 1,195,000 incentive stock options under the Company's Stock Option Plan, of which 810,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.31 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant.*

1. Provide details of any loans to or by Related Persons.

*Not applicable.*

1. Provide details of any changes in directors, officers, or committee members.

*In May 2023, Mr. Mark Lievonen, CM, who joined the board of Sona in December 2020, assumed the role as Chair of the Board. Mr. Lievonen served as president of Sanofi Pasteur Limited from 1999 to 2016, during which time it became a billion-dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets. A corporate director and principal of JML Advisory Services, Mr. Lievonen also co-chairs Canada’s COVID-19 Vaccine Task Force. Mr. Lievonen also serves on a number of public companies and not-for-profit boards, and as an advisor to other businesses and institutions. Mr. Lievonen succeeds Mr. Jim Megann, principal of Numus Financial, who will continue to serve as a director of Sona.*

*As a result of the acquisition of Siva Therapeutics Inc. in March 2023, Leonard Pagliaro, Ph.D., CEO of Siva now serves as a Sona Director, Chief Scientific Officer and president of Sona’s wholly owned US subsidiary, Siva Therapeutics, Inc.*

*In January 2024, Dr. Michael Gross retired from the Company’s Board of Directors to focus on other business interests.*

*In March 2024, the Company named Dr. Carman Giacomantonio, MD, MSc., FRCSC, to its Advisory Board. Dr. Giacomantonio is a surgical oncologist and professor of surgery whose research focuses on the mechanism of action of interleukin-2 therapy in the treatment of melanoma and breast and colorectal cancer. Dr. Giacomantonio is the principal investigator for the Company’s current pre-clinical efficacy study at Dalhousie University.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*Not applicable.*

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there are no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2024

 Name of Director or Senior Officer

 Rob Randall

 (Signed) *Rob Randall*
CFO & Corporate Secretary

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerSONA Nanotech Inc. | For Month EndApril 2024 | Date of ReportYY/MM/DD2024/05/06 |
| Issuer Address1 Research Drive, Bay 2 |
| City/Province/Postal CodeDartmouth, Nova Scotia, Canada, B2Y4M9 | Issuer Fax No.(902) 491-4281 | Issuer Telephone No.(902) 442-0653 |
| Contact NameDavid Regan | Contact PositionChief Executive Officer  | Contact Telephone No.(902) 536-1932 |
| Contact Email Addressdavid@sonanano.com | Web Site Addresshttps://sonanano.com/ |